Jim Cramer - Mad Money Cardinal Health Inc CAH-N DON'T BUY May 14, 2025

In pharma space, prefers growthy areas such as distributors like CAH and MCK.

XLV gives you a basket of names, with some winners and some losers. LLY is the top holding, that's a winner. Also holds JNJ and PFE, which haven't done particularly well. 

He owns NVO, MCK and CAH. He likes those companies where the only serious competition comes from 1 or 2 others, as they can control pricing power. Diabetes and weight loss are definite growth areas. See his Top Picks.

Scores 4/10 on value, 3/10 on fundamentals. Try to avoid. If you're in it and looking for an exit, now's not a bad time because it's had a pop YTD. Only about 4% more upside to analysts' price targets.

She prefers larger, less volatile companies that are a bit more secure. Try UNH or big US pharmaceuticals.

Last week, they reported a top and bottom line beat and raised guidance. Q4 revenue grew 12% YOY

Likes, and owns. As people age, volume of drugs required can only increase, benefiting a name like this.

Healthcare space provides nice combination of growth with stability, in case we get into latter stage of economic cycle. 

3rd largest pharmacy distributor in the USA. Good job at new products and pricing strategy. Has recently streamlined operations. However, stock price fully valued. Would recommend buying on weakness (below $95/share). 

9% forecast growth rate, trading ~14x forward PE. Not a bad valuation to growth rate. Great chart of higher highs and higher lows. Outpacing S&P since late 2021. Pricing power and favourable demographics. Yield is 1.6%.

All-time high today. Probably overbought, with RSI at 77, so don't buy more today. Very little competition. Pricing power. Aging demographics. US medication usage can only increase over time, especially weight-loss segment.